A case series on the efficacy and safety of a PD-1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI-H endometrial cancer.

ABSTRACT:

Background

Endometrial cancer (EC) is one of the most common gynecological malignancies in developed countries worldwide. The treatment of recurrent endometrial cancer is a very difficult problem in clinical work. Studies on patients with recurrent EC microsatellite instability-high (MSI-H) are very rare. The objective of this study is to initially evaluate the therapeutic effect of a PD-1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI-H endometrial cancer.

Methods

Eight patients with recurrent MSI-H endometrial cancer were recruited from Tianjin Medical University Cancer Institute and Hospital from July 2019 to July 2021, and their median age was 55.3 (range, 46-62) years. All patients experienced recurrence after surgical treatment, and the

SUBMITTER: Song H 

PROVIDER: S-EPMC10493622 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature